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Increased risk and severity of idiopathic pulmonary arterial hypertension (iPAH) is 
associated with elevated plasma estradiol (E2) in both men and postmenopausal women (1, 
2), suggesting that E2 is not ovarian-derived. Aromatase is responsible for the synthesis of 
E2. Remodelled pulmonary arteries, lesions and human pulmonary artery smooth muscle 
cells (hPASMCs) from PAH patients have high levels of aromatase (3). CYP1B1 can convert 
E2 to mitogenic 16-hydroxy-estrogens (16OHEs) and this enzyme is over-expressed in 
diseased pulmonary arteries from PAH patients (4). Existing assays have not been sensitive 
or specific enough to detect levels of many E2 metabolites in PAH patient blood. Using a 
newly developed liquid chromatography tandem mass spectrometry (LC-MS/MS) assay (5), 
here we investigate the profile of several E2 metabolites in iPAH patients. 
Methods 
Serum from 22 subjects with iPAH (12 males, 10 females) and 34 healthy control subjects 
(17 males, 17 females) were analysed by LC-MS/MS for estrone (E1), 17α-estradiol 
(17αE2), 17β-estradiol (E2), 16-Hydroxyestrone (16OHE1), 16-Hydroxyestradiol (16OHE2), 
2-methoxyestrone (2MeOE1), 4-methoxyestrone (4MeOE1), 2-methoxyestradiol (2MeOE2) 
and 4-methoxyestradiol (4MeOE2) (5). Data were compared by a Mann-Whitney U-test with 
associations assessed using Pearson’s correlations. Values below the confirmed limit of 
quantification (LOQ) were imputed as the LOQ (2pg/mL E1, E2, 16OHE2, 2MeOE1 and 
6pg/mL 16OHE1).  
To determine if 16OHE2 was present at bioactive concentrations, proliferation was studied in 
hPASMCs and cell migration studied in human blood outgrowth endothelial cells (BOECs). 
hPASMCs were isolated from distal pulmonary arteries (0.3 – 1 mm diameter) from 
macroscopically normal controls or patients undergoing lung transplantation. BOECs were 
isolated from PAH patients as described previously (6) with cells cultured as described 
previously (7). The patients were male and female (heritable PAH/iPAH).  Cells were 
stimulated with 16OHE2 following preliminary concentration-response analysis (10nM 
hPASMCs and 1nM BOECs) for 48 hours in phenol red-free media.  Cell counts and cell 
migration (Corning® Transwell inserts) were assessed using a Countess II FL cell counter 
(Life Technologies, UK). A student’s t-test was applied for comparison of 16OHE2 vs vehicle 
treated cells for each group. 
Results 
E1 was decreased in serum of female iPAH patients whilst 16OHE2 was increased. E1, E2 
and 16OHE1 were elevated in male iPAH patients (Table 1). Comparing males and females, 
E1 was higher in female controls compared with male controls (p=0.01). In iPAH, E1 was 
higher in males than females (P=0.03).  
In female iPAH patients, increased E1 was associated with increasing PAWP (R2= 0.5, β= 
0.7, p=0.03), decreased E2 was associated with increasing age (R2=0.7, β= -0.8, p=0.02), 
and increasing E2 with increasing PAWP (R2=0.6, β = 0.6, p= 0.05) while increased 16OHE1 
correlated with a reduction of cardiac output (R2=0.7, β = -0.6, p=0.01). In male iPAH, 
increased E2 was associated with increased PAWP (R2=0.5, β=0.6, p=0.02) while increased 
E1 and E2 associated with increasing BNP levels (R2=0.6, β=0.8, p=0.01 and R2=0.4, β=0.6, 
p=0.04). 
16OHE2 caused proliferation of hPASMCs from female PAH patients (by 63%) but not 
controls (male or female) (Figure 1A-C). 16OHE2 caused increased migration of BOECs 
from PAH patients, both in males (by 55%) and females (by 67%) (Figure 1D). 
 
Discussion 
This study is the first to simultaneously quantify several estrogens in controls and PAH 
patients as our methodological paper measured levels in pooled plasma samples (5). LC-
MS/MS allowed discrimination between isomers of estradiol and its bioactive metabolites 
such as 16OHE1, 16OHE2 and methoxyestrogens. Increased 16-hydroxylation of E1/E2 
promotes formation of proliferative metabolites and we identified accumulation of 16OHE2 in 
female iPAH patient serum for the first time. We confirmed increased levels of 16OHE1 in 
patients which had been suggested by previous studies (8, 9). In female iPAH, 16OHE2 was 
also increased. There was increased E1 and E2 levels in male iPAH patients, consistent with 
a previous study using immunoassay detection (1). The E2 concentrations we determined 
here were lower compared with previous studies determined using immunoassays.  This is 
consistent with immunoassays being limited by cross-reactivity and over-estimation of E2 
levels compared with LC-MS/MS (10).   
Aromatase and CYP1B1 are increased in PAH patient pulmonary arteries and pulmonary 
vascular lesions (3, 4). Increased aromatase activity may account for increased plasma E2 
in men and post-menopausal women with iPAH (1, 2). In female iPAH, there was a decrease 
in E1 with no change in E2. The change in E1 may reflect an increased conversion to 
16OHEs via CYP enzymes as reflected by increased 16OHE1 and 16OHE2 in these 
patients. Where there is a decrease in E1 with no change in E2 this could also be due to the 
increased metabolism of E2. Baird et al. recently demonstrated that E2 levels are elevated in 
post-menopausal iPAH female patients compared with controls; however, E2 levels from 
controls in that study were 5-7 pg/mL, commensurate with post-menopause levels (2). The 
majority of females in this current study were pre-menopausal, with sampling not routinely 
timed to consider menstrual cycle, and mean E2 concentrations in controls and patients 
were ~34 pg/mL. Hence, it is perhaps unlikely that a further increase would be expected in 
this patient cohort. Future clinical studies could consider blood sampling from pre-
menopausal women at the same stage of the menstrual cycle. 3  
As 16OHE1 can be derived directly from E1 and male patients have higher E1, this may also 
contribute to the elevated 16OHE1 in these patients. Consistent with increased 16OHEs 
observed in iPAH patients, polymorphisms in CYP1B1 are observed in PAH patients 
associated with functional differences in 16-hydroxylation, cancer risk and E2-mediated 
carcinogenicity (11, 12). Conversion of E2 to 16OHE1 by CYP1B1 may contribute to the 
pathogenesis of experimental pulmonary hypertension and cause proliferation of hPASMCs 
via increased oxidative stress (7, 8).  
We have already demonstrated that 16OHE1 can cause proliferation of both male and 
female hPASMCs and male mouse PASMCs at concentrations observed in plasma (4, 7, 
13). 16OHE1 acts through the ERa receptor in hPASMCs (7, 14) and indeed we have 
shown that ERa receptors are more highly expressed in female PAH hPASMCs (15). This is 
consistent with female hPASMCs being more proliferative to E2, also due to decreased 
basal bone morphogenetic protein receptor II (BMPRII) signalling in female hPASMCs [16]. 
16OHE2 is a novel metabolite with unknown effects that was increased in the serum from 
female iPAH patients compared with controls. This could also be due to altered CYP1B1-
mediated 16-hydroxlation (4, 13). 16OHE2 is an E2-receptor agonist, capable of cellular 
proliferation associated with cancer risk and E2-mediated carcinogenicity (12). Consistent 
with this, we now show that, at a pathophysiological concentration, 16OHE2 can also induce 
proliferation in female human PAH PASMCs with no effect in female or male control 
PASMCs where ERa expression is not so high. However, we show that 16OHE2 increases 
cell migration in both male and female PAH BOECs. As 16OHE1 has been shown to act as 
a ‘second hit’ to uncover a pulmonary hypertensive phenotype in BMPRII mutant male and 
female mice [9], this suggests that both 16OHE1 and 16OHE2 may also facilitate pulmonary 
vascular remodelling in males and females by acting as a ‘second hit’ to BMPRII mutations. 
16OHE2 is also produced in abundance during pregnancy and it is interesting to speculate 
that it may contribute to pregnancy being a risk factor for PAH (17).  
It should be noted that all of the medications that the patients were prescribed are 
metabolised in the liver by CYP enzymes such as CYP3A4 and CYP2C9/8 and have no 
known effects on lung or liver CYP1B1 or CYP1A1 activity. One limitation of this study is that 
the patients were older than the controls. However E2 and 16OHE1 levels correlated with 
indicators of disease severity within the patient groups and decreased E2 was associated 
with increasing age in iPAH patients. This suggests that increased E2/metabolite levels in 
PAH patients and are related to disease status rather than difference in age. 
The results suggest that estrogen metabolism is altered in PAH and both 16OHE1 and 
16OHE2 accumulate, with 16OHE1 levels relating to disease severity. This study is limited 
by the small size but important as it warrants further multi-center fully powered studies to 
confirm and correlate metabolite levels with severity and sub-groups of PAH. Future studies 
on CYP enzymes and CYP1B1 inhibitors in patients with PAH may also be valuable. 
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Subjects 17 10  17 12  
Clinical  
Characteristics 
      
Age (y)  39.0 [31 – 45] 56.5 [43 - 61] 0.01 32.5 [27 – 37] 57.0 [50 – 62] 0.001 
BMI (kg·m−2) 24.9 [22 – 28]  29.1 [28 – 31] 0.06 23.8 [22 – 33] 32.8 [29 – 34] 0.07 
Right Atrial Pressure (mmHg)  6.0 [4 – 10]   9.0 [7 - 14] 0.23 
mPAP (mmHg)  55.0 [35 - 62]   51.5 [40 - 60] 0.97 
Cardiac Output (L/min)  5.3 [5 - 7]   4.6 [4 - 6] 0.38 
PAWP (mmHg)  9.0 [8 - 12]   11.0 [9 - 16] 0.23 
PVR (mmHg/l∙min)  9.0 [4 - 13]   9.1 [4 -11] 0.97 
BNP (pg/mL)  76.0 [25 - 238]   114.0 [21 - 350] 0.79 
Current PAH Medications       
ERA  3   4  
PDE5 Inhibitor  2   4  
Epoprostenol or Trepostinil  2   2  
Calcium Channel Blocker  -   1  
Treatment Naïve  -   1  
Estrogen Concentrations 
(pg/mL) 
      
E1 34.9 [27 – 75] 
(100) 
16.9 [9 – 34] 
(91) 
0.02 23.6 [17 – 32] 
(100) 
28.1 [24 – 55] 
(100) 
0.05 
E2 16.8 [10 – 59] 
(100) 
7.9 [4 – 65] 
(100) 
0.15 16.0 [10 – 21] 
(100) 
21.3 [19 – 30] 
(100) 
0.02 
16OHE1 24.8 [11 – 38] 
(65) 
29.8 [17 – 53] 
(91) 
0.09 24.1 [19 – 32] 
(47) 
79.9 [58 - 96] 
(75) 
0.01 
16OHE2 10.7 [9 – 11] 
(18) 
14.6 [8 – 26] 
(82) 
0.01 15.4 [8 – 18] 
(41) 
15.9 [6 – 3]  
(67) 
0.24 
2MeOE1 8.4 [6 – 26] 
(41) 
6.9 [6 – 80] 
(55) 





4MeOE1 ND ND - ND ND - 
2MeOE2 ND ND - ND ND - 
4MeOE2 ND ND - ND ND - 




    
E1 33.7 [27 - 48] 39.5 [24 - 52] 1.00    
E2 24.0 [12 - 64] 47.7 [25 - 88] 0.57    
16OHE1 21.9 [12 - 35] 34.4 [16 - 52] 0.23    
16OHE2 10.1 [9 - 11] 14.0 [10 - 15] 0.06    
2MeOE1 8.4 [7 - 18] 7.0 0.64    




    
E1 78.6 [56 - 
107] 
12.1 [9 - 19] 0.02    
E2 9.6 [7 -13] 4.6 [3 - 7] 0.26    
16OHE1 37.7 29.8 [27 - 38] 0.38    
16OHE2 16.5 21.1 [9 - 28] 0.26    
2MeOE1 16.0 [11 – 21] 6.5 [6 - 36] 0.90    
Endothelin receptor antagonist, ERA; Phosphodiesterase type 5 inhibitor, PDE5; Pulmonary arterial hypertension, PAH; idiopathic PAH, iPAH; Mean pulmonary 
artery pressure, mPAP; Pulmonary artery wedge pressure, PAWP; Pulmonary Vascular Resistance, PVR; B-type natriuretic peptide, BNP; Not Detected, ND; 
Estrone, E1; Estradiol, E2; 16-Hydroxyestrone, 16OHE1; 16-Hydroxyestradiol, 16OHE2; 2-Methoxyestrone, 2MeOE1; 4-Methoxyestrone, 4MeOE1; 2-
Methoxyestradiol, 2MeOE2; 4-Methoxyestradiol, 4MeOE2. Medication details of 3 female patients is unknown. Clinical characteristics and estrogen Levels 







Figure 1: 16OHE2 stimulation increases proliferation and migration of human cells  
10 nM 16OHE2 increases proliferation in female PAH (A) with no effect on female control (B) and male control (C) human PASMCs. 1 nM 
16OHE2 increased migration of male and female BOECs derived from PAH patients (D). Data shown as Mean ± SEM (n= 4 - 6) with statistics 
performed by comparison of 16OHE2 to veh by a student’s t test *p<0.05, **p<0.01. Veh = Vehicle Control, Ethanol. 
